Abstract:Regulatory T cells (T regs ) make major contributions to immune homeostasis. Because T reg dysfunction can lead to both allo- and autoimmunity, there is interest in correcting these disorders through T reg adoptive transfer. Two of the central challenges in clinically deploying T reg cellular therapies are ensuring phenotypic stability and maximizing potency. Here, we describe an approach to address both issues through the creation of OX40 ligand (OX40L)–specific chimeric antigen receptor (CAR)–T regs under the control of a synthetic forkhead box P3 ( FOXP3 ) promoter. The creation of these CAR-T regs enabled selective T reg stimulation by engagement of OX40L, a key activation antigen in alloimmunity, including both graft-versus-host disease and solid organ transplant rejection, and autoimmunity, including rheumatoid arthritis, systemic sclerosis, and systemic lupus erythematosus. We demonstrated that OX40L–CAR-T regs were robustly activated in the presence of OX40L-expressing cells, leading to up-regulation of T reg suppressive proteins without induction of proinflammatory cytokine production. Compared with control T regs , OX40L–CAR-T regs more potently suppressed alloreactive T cell proliferation in vitro and were directly inhibitory toward activated monocyte-derived dendritic cells (DCs). We identified trogocytosis as one of the central mechanisms by which these CAR-T regs effectively decrease extracellular display of OX40L, resulting in decreased DC stimulatory capacity. OX40L–CAR-T regs demonstrated an enhanced ability to control xenogeneic graft-versus-host disease compared with control T regs without abolishing the graft-versus-leukemia effect. These results suggest that OX40L–CAR-T regs may have wide applicability as a potent cellular therapy to control both allo- and autoimmune diseases.

Regulatory T cells engineered with TCR signaling–responsive IL-2 nanogels suppress alloimmunity in sites of antigen encounter

Generation Of Human Regulatory Gamma Delta T Cells By Tcr Gamma Delta Stimulation In The Presence Of Tgf-Beta And Their Involvement In The Pathogenesis Of Systemic Lupus Erythematosus

Nanoparticles loaded with IL-2 and TGF-β promote transplantation tolerance to alloantigen

Engineered Regulatory T Cells Prevent Graft-Versus-host Disease While Sparing the Graft-Versus-leukemia Effect after Bone Marrow Transplantation.

Human OX40L-CAR-Tregs target activated antigen-presenting cells and control T cell alloreactivity

Suppression of allograft rejection by regulatory B cells induced via TLR signaling

Human OX40L–CAR-T regs target activated antigen-presenting cells and control T cell alloreactivity

Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression

Polyclonally Derived Alloantigen-Specific T Regulatory Cells Exhibit Target-Specific Suppression and Capture MHC Class II from Dendritic Cells

Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance

Selective expansion of regulatory T cells using an orthogonal IL-2/IL-2 receptor system facilitates transplantation tolerance

Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients

Ex Vivo Expansion of Human Tregs Specific for Alloantigens Presented Directly or Indirectly.

Induced regulatory T cells modified by knocking down T-bet in combination with ectopic expression of inhibitory cytokines effectively protect graft-versus-host disease.

Antigen-Dependent Suppression of Alloresponses by Foxp3-Induced Regulatory T Cells in Transplantation

Bio-inspired controlled release for regulatory T cell recruitment in vivo (144.3)

Efficient Generation of Human Alloantigen-Specific CD4+ Regulatory T Cells from Naive Precursors by CD40-activated B Cells

Regulatory T Cells Nanoextinguisher to Manipulate Multiple Immune Evasion for Immunotherapy

Suppression of lethal autoimmunity by regulatory T cells with a single TCR specificity

T cell receptor gene‐modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft‐versus‐host disease

Regulatory T lymphocytes as a treatment method for rheumatoid arthritis - Superiority of allogeneic to autologous cells